The purpose of this study is to describe, under real-world conditions, the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE)
This study is designed to test a potential biomarker to identify NCP patients. A biomarker is a characteristic that is unique to NCP patients and will help to identify them from DED patients so that correct treatment can be provided to them.
The purpose of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation Device (“Vanquish”) in subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer
Cardiogenic shock (CS) is a dangerous clinical condition where the heart’s ability to pump blood is so compromised that it cannot support the vital functions of the rest of the body. CS has an increased risk of death of 50-60%, and despite tremendous research effort over the last decade, survival outcomes have not changed over this period. Current treatment for CS often involves mechanical circulatory support (MCS) devices, which are mechanical pumps that help support blood flow to the body.
Approximately 230,000 women are diagnosed with invasive breast cancer and 60,000 women are diagnosed with ductal carcinoma in situ (DCIS) (breast cancer in the breast milk ducts) annually in the US. Most women choose to be treated with breast conserving surgery (BCS). The goal of BCS is to resect the tumor with a surrounding margin of tissue free of cancer, and to minimize the volume of tissue removed, thereby preserving the overall shape and appearance of the breast.
The study is being conducted to compare whether an optical correction of bifocal spectacle lenses (BFL) or single-vision spectacle lenses (SVL) is more effective for the treatment of children with esotropia greater at near. Children will be randomized to be treated with BFLs or SVLs for 3 years and be evaluated at regular intervals throughout the study to determine whether their condition has worsened.
REACH is a program to energize and empower people living with lupus through movement. The REACH Lupus study is a randomized controlled pilot study to evaluate the REACH program.
This is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial evaluating antiviral and other therapeutics for use in the treatment of Post-Acute Sequelae of COVID-19 (PASC). The hypothesis is that persistent viral infection and/or overactive/chronic immune response are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.
Evaluate the correlation between ICU Skeletal muscle loss and protein intake and investigate the lack of daily protein intake by the presence of loss of rectus femoris muscle quantity and quality.
The proposed study compares Tai Chi + Routine Care with Routine Care alone to see if the addition of Tai Chi to Routine Care can improve Knee OA pain. The study will be conducted at Tufts Medical Center, UCLA, Boston Medical Center, and Cleveland Clinic. The study is funded by the National Institutes of Health National Center for Complementary and Integrative Health. We expect to enroll up to 480 subjects across all sites needed to complete the study
REACT-AF is a multicenter, prospective, randomized clinical trial comparing two treatment strategies for stroke prevention in patients with a history of paroxsymal or persistent atrial fibrillation and moderate stroke-risk.
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
The goal of this study is to develop a faster, safer, and more accurate method for determining if a newborn has an infection. This study involves analyzing saliva for markers of infection and inflammation known as cytokines. We will analyze infant’s saliva repeatedly for inflammatory biomarkers within the first 36 hours of their standard of care treatment. We hypothesize that levels of these cytokines will more quickly predict which babies are truly infected and which babies are not compared to the blood test currently being used.
The aims of the study are:
This study will evaluate infant vision health based on the history of prenatal drug exposure. Data from this study will be used to create a new process which will include vision health as part of the discharge planning for infants with prenatal drug exposure admitted to Tufts Children’s Hospital
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
SATURN is a multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial. A total of 1,456 patients presenting within 7 days of a spontaneous lobar ICH while taking statins will be randomized to one of two treatment strategies: discontinuation vs. continuation of statin therapy (using the same agent and dose that they were using at ICH onset).
The purpose of this research study is to explore the challenges of recognizing stroke in young adults, the process of making treatment decisions, and the patient’s understanding of the risk of recurrence and long term consequences of stroke. This study consists of a 30 to 60 minute interview of patients with prior stroke (ischemic stroke, transient ischemic attack, or intracerebral hemorrhage) who were 18-50 years of age at the time of stroke onset.
The primary objective of this study is to assess the efficacy of rifaximin SSD-40IR versus placebo to delay the occurrence of HE-related hospitalization.
This is a Prospective, multi‐center, international, randomized controlled, post‐market trial.
